August 2024 in “Journal of Cutaneous and Aesthetic Surgery” This study found significant hair growth improvement with microneedling radiofrequency treatment in most patients with patterned hair loss, with minimal short-term adverse effects.
November 2023 in “Indian Dermatology Online Journal” This study found that tofacitinib was safe and effective for patients with severe or treatment-resistant alopecia areata, alopecia totalis, and alopecia universalis, resulting in significant hair regrowth for most participants.
May 2023 in “International Journal of Trichology” In this study, PRP therapy did not show significant effectiveness in treating androgenetic alopecia in patients over a 6-month period, with 45% of participants reporting no improvement in hair growth, although adverse effects were minimal and non-serious.
3 citations
,
November 2021 in “Applied Microscopy” This article presents a comprehensive overview of hair microscopy techniques and their diagnostic potential for systemic and cutaneous disorders, emphasizing its usefulness in resource-limited settings and highlighting the underutilization of this non-invasive method due to lack of awareness.
2 citations
,
September 2024 in “Lasers in Surgery and Medicine” This study concluded that noninvasive imaging techniques offer potential benefits in managing scalp conditions by potentially reducing the need for biopsies and minimizing patient morbidity, each technique having unique advantages and limitations for specific conditions.
2 citations
,
January 2014 in “Archives of Aesthetic Plastic Surgery” The authors concluded that total hairline correction, which addresses multiple areas beyond the frontotemporal recess, is more effective in improving aesthetic facial balance for women with M-shaped or rectangular hairlines.
1 citations
,
June 2025 in “Journal of Allergy and Clinical Immunology Global” This study describes the case of a young boy with Netherton syndrome who showed significant improvements in skin inflammation, quality of life, and hair growth after receiving dupilumab, with a marked decrease in serum IgE levels observed following treatment.
This source reports that telogenic hair loss, while not leading to complete baldness, significantly impacts patients' quality of life due to its effects on their psychoemotional state; no standardized treatment currently exists, so therapy focuses on addressing trigger factors and psychological well-being.
May 2024 in “Journal of cosmetic dermatology” This study found that topical finasteride mixed with minoxidil improved hair appearance and self-esteem in men with androgenetic alopecia, but it was not superior to oral finasteride and had lower treatment adherence.
August 2023 in “Journal of the American Academy of Dermatology” A scalp biopsy is essential for accurately diagnosing alopecia, with a 4-mm punch biopsy sectioned horizontally being the recommended technique according to this study.
January 2023 in “DIGITAL HEALTH” This study found that users of a German direct-to-consumer teledermatology platform for finasteride reported improvements in hair appearance and self-esteem, though 12% experienced treatment-related adverse events.
15 citations
,
July 2022 in “Biomedicines” This study found no significant difference in the severity of alopecia areata between treatments with platelet-rich plasma and triamcinolone acetonide; further high-quality trials of PRP are needed.
December 2024 in “PLoS ONE” In this study, researchers evaluated male-pattern hair loss treatments using RNA and microRNA expression profiling in 91 male participants, identifying 52 differentially expressed genes and suggesting a potential role for personalized treatment based on genetic analysis to monitor and predict treatment efficacy and compliance.
10 citations
,
November 2017 in “Skin Appendage Disorders” This series of eight North American patients with erosive pustular dermatosis of the scalp suggests that factors like immunosenescence and ultraviolet damage may contribute to the condition's development.
7 citations
,
January 2023 in “Anti-Cancer Drugs” In this study, researchers reviewed cases of EGFR inhibitor-induced folliculitis decalvans and reported the first known occurrences associated with afatinib in three female NSCLC patients, highlighting the importance of early diagnosis and management to improve patient quality of life.
4 citations
,
March 2025 in “Pediatric Dermatology” This review examines the clinical presentation of alopecia areata in children and compares it to adult-onset cases, noting that data on pediatric cases is scarce and often varies, with reported onset typically between ages 6 and 12.
4 citations
,
September 2021 in “Dermatopathology” This study suggests that erosive pustular dermatosis of the scalp may be part of the spectrum of autoinflammatory dermatoses, rather than a unique skin disorder.
1 citations
,
April 2024 in “Journal of Clinical Medicine” This study found that patients with severe alopecia areata demonstrated reduced corneal sensitivity and increased corneal staining, and exhibited altered topographic and biomechanical eye parameters compared to controls, suggesting a possible increased risk of keratoconus and the necessity for regular ophthalmological exams.
November 2025 in “Journal of Clinical Medicine” This review article explores the potential systemic nature of alopecia areata, highlighting the association with ocular abnormalities and suggesting that shared pathogenic pathways may lead to eye symptoms occurring at younger ages than usual.
October 2025 in “Diagnostics” In this case study, an 18-year-old woman's triangular alopecic patch diagnosed as temporal triangular alopecia was considered non-progressive and had no impact on her quality of life, so no treatment was initiated.
July 2025 in “Frontiers in Medicine” In this systematic review and meta-analysis, the authors examined single-spin versus double-spin centrifugation protocols for PRP in patients with androgenic alopecia and found no significant difference in platelet concentration, hair density, or hair types between the protocols.
This review analyzed literature on primary cutaneous lymphomas involving the scalp, finding that scalp involvement in these cases often leads to non-scarring focal alopecia and may indicate more aggressive disease.
March 2025 in “Journal of Clinical Medicine” This study reviewed adverse events associated with low-dose oral minoxidil for treating alopecia, finding hypertrichosis and fluid retention as common, typically manageable side effects without needing treatment discontinuation.
June 2024 in “Computational and Structural Biotechnology Journal” This review discusses the integration of omics analyses in androgenetic alopecia research, reporting no new clinical results but suggesting that collaborative multi-omics studies may enhance understanding of AGA's pathomechanisms.
January 2024 in “Biomedicines” This study found that a single injection of autologous cell micrografts significantly improved hair condition in women with androgenetic alopecia six months post-treatment.
1 citations
,
January 2021 in “Our Dermatology Online” This case report describes an adult initially diagnosed with alopecia areata but was later found to have tinea capitis, successfully treated with terbinafine and ketoconazole shampoo.
4 citations
,
January 2019 in “PubMed” This study found that women with female pattern hair loss had significant hormonal imbalances, specifically involving adrenal androgens, suggesting these may play a central role in the condition's development.
3 citations
,
November 2021 in “Clinical, Cosmetic and Investigational Dermatology” In this study, a single application of autologous cellular micrografts showed short-term favorable responses in up to two-thirds of patients with androgenetic alopecia.
February 2026 in “Bioengineering” This preliminary study suggests that hyperbaric oxygen therapy may improve scalp health and follicle activation in healthy adults, with subjective assessments showing significant improvements despite mixed objective findings.
July 2025 in “Actas Dermo-Sifiliográficas” This study found that a single session of botulinum toxin, whether administered subcutaneously or combined intramuscularly and subcutaneously, did not significantly improve hair density or hair quality in men with androgenetic alopecia after six months.